Compounds isolated from Curcuma aromatica Salisb

Author(s): Bamba Y, Yun YS, Kunugi A, Inoue H

Abstract

Curcuma species (Zingiberaceae) are used as both food and medicine in Asia. Ten sesquiterpenes (1-10) and two curcuminoids (11 and 12) were isolated from the rhizomes of Curcuma aromatica Salisb. and identified. The compounds were evaluated for their ability to inhibit cytochrome P450 (CYP). Among them, the sesquiterpene (4S,5S)-(+)-germacrone-4,5-epoxide (7) inhibited certain subtypes of CYP more potently than or at levels comparable to the curcuminoids curcumin (11) and demethoxycurcumin (12); 7 (IC(50) = 1.0 ± 0.2 μM) > 12 (IC(50) = 7.0 ± 1.7 μM) > 11 (IC(50) = 14.9 ± 1.4 μM) for CYP3A4 inhibition; 12 (IC(50) = 1.4 ± 0.2 μM) > 11 (IC(50) = 6.0 ± 1.4 μM) > 7 (IC(50) = 7.6 ± 2.5 μM) for CYP2C9 inhibition; and 7 (IC(50) = 33.2 ± 3.6 μM) = 12 (IC(50) = 34.0 ± 14.2 μM) > 11 (IC(50) > 100 μM) for CYP1A2 inhibition. These results suggest the possibility that Curcuma aromatica Salisb. may cause food-drug interactions via cytochrome P450 inhibition by sesquiterpene 7 and curcuminoids 11 and 12.

Similar Articles

Trends in alternative medicine use in the United States, 1990-1997: results of a follow-up national survey

Author(s): Eisenberg DM, Davis RB, Ettner SL, Appel S, Wilkey S, et al.

Systematic review of herbs and dietary supplements for glycemic control in diabetes

Author(s): Yeh GY, Eisenberg DM, Kaptchuk TJ, Phillips RS

Curcumin: From ancient medicine to current clinical trials

Author(s): Hatcher H, Planalp R, Cho J, Torti FM, Torti SV

Evaluation of liposomal curcumin cytochrome p450 metabolism

Author(s): Mach CM, Chen JH, Mosley SA, Kurzrock R, Smith JA

Liquid chromatographic method for the determination of rosiglitazone in human plasma

Author(s): Kolte BL, Raut BB, Deo AA, Bagool MA, Shinde DB

Hypoglycaemic effect of Artemisia herba alba

Author(s): al-Shamaony L, al-Khazraji SM, Twaij HA

Effects of curcumin on cytochrome P450 and glutathione S-transferase activities in rat liver

Author(s): Oetari S, Sudibyo M, Commandeur JN, Samhoedi R, Vermeulen NP

Inhibition of human recombinant cytochrome P450s by curcumin and curcumin decomposition products

Author(s): Appiah-Opong R, Commandeur JN, van Vugt-Lussenburg B, Vermeulen NP

Structure-activity relationships for the inhibition of recombinant human cytochromes P450 by curcumin analogues

Author(s): Appiah-Opong R, de Esch I, Commandeur JN, Andarini M, Vermeulen NP

Bioavailability of curcumin: problems and promises

Author(s): Anand P, Kunnumakkara AB, Newman RA, Aggarwal BB

Curcumin therapeutic promises and bioavailability in colorectal cancer

Author(s): Shehzad A, Khan S, Shehzad O, Lee YS

Pharmacokinetics and Pharmacodynamics of Curcumin

Author(s): Sharma RA, Steward WP, Gescher AJ

Evaluation of liposomal curcumin cytochrome p450 metabolism

Author(s): Mach CM, Chen JH, Mosley SA, Kurzrock R, Smith JA